Results 71 to 80 of about 362,020 (233)

The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age

Human Vaccines & Immunotherapeutics, 2022
The quadrivalent human papillomavirus (4vHPV) vaccine has shown confirmative effectiveness in preventing HPV-related diseases among women and men around the globe. The phase III, randomized, double-blind efficacy study (Base study, NCT00834106) conducted
Chao Zhao, Yun Zhao, Jingran Li, Mingzhu Li, Yanyan Su, Xin Mi, Su Yi La Tu, Danhua Shen, Lihua Ren, Yanyan Li, Linhong Wang, Lihui Wei   +11 more
doaj   +1 more source

Delivery mode and maternal health conditions before and after childbirth: A population‐based cohort study from Estonia

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
Cesarean section is associated with higher rates of chronic health conditions and pregnancy‐related complications, whereas vaginal delivery is more commonly linked to pelvic floor and perineal complications. These findings emphasize the need for individualized decision‐making and thorough counseling about the risks and benefits of each delivery method.
Katrin Täär, Helle Karro, Merli Saare, Reedik Mägi, Estonian Biobank Research Team, Andres Metspalu, Lili Milani, Tõnu Esko, Mait Metspalu, Mari Nelis, Georgi Hudjashov, Andres Salumets, Triin Laisk, Maire Peters   +13 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann, Ulrike Wieland, Steffi Silling, Frank Oellig, David Chromy, Julia Hyun, Thilo Gambichler, Alexander Kreuter   +7 more
wiley   +1 more source

Scalp Dysesthesia: Emerging Pathophysiologic Insights and Therapeutic Implications

International Journal of Dermatology, EarlyView.
Scalp dysesthesia is a chronic condition diagnosed through exclusion. This scoping review synthesized data from 59 patients to identify recurrent clinical features, comorbidities, and management strategies that may support earlier diagnosis. Emerging patterns suggest that neuronal sensitization may underlie common symptoms.
Aditya K. Gupta, Jaspreet Kaur, Amanda Liddy, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

The role of immunohistochemical research at the diagnosis of neoplastic lesions of the cervix [PDF]

Гинекология, 2016
The analysis of literature data about the use of immunohistochemical markers for the diagnosis and differential diagnosis of cervical lesions. The most significant assistance in identifying and determining the degree of cervical intraepithelial neoplasia
A I Shchegolev, O D Mishnev
doaj  

Triage Performance of FAM19A4/miR124‐2 Methylation: 18‐Month Follow‐Up Results From a Prospective Observational Study Within the Dutch Primary HPV‐Based Cervical Screening Program

International Journal of Cancer, Volume 159, Issue 10, Page 2463-2472, 15 November 2026.
ABSTRACT DNA methylation analysis of the genes FAM19A4 and miR124‐2 has emerged as a promising triage strategy for high‐risk (hr) human papillomavirus (HPV)‐positive women in cervical screening. This study reports a prospective evaluation of the diagnostic accuracy of FAM19A4/miR124‐2 methylation in a large population‐based primary HPV‐based screening ...
Lisanne Verhoef, Mila S. Griffioen, Maaike C. G. Bleeker, John W. J. Hinrichs, Albert G. Siebers, Albertus T. Hesselink, Chris J. L. M. Meijer, Renske D. M. Steenbergen, Johannes Berkhof, Daniëlle A. M. Heideman   +9 more
wiley   +1 more source

Cervical screening in Australia 2010-2011 [PDF]

, 2013
This paper presents the latest national statistics monitoring the National Cervical Screening Program, which aims to reduce incidence, morbidity and mortality from cervical cancer.Summary:The National Cervical Screening Program (NCSP) aims to reduce

core  

Cervical Intraepithelial Neoplasia, Cervical Cancer, and HPV [PDF]

Annual Review of Public Health, 1996
Major progress has been made to control cervical cancer in the United States and Europe using screening programs, although it remains a major cause of morbidity and mortality in the developing world. The association between cervical cancer and a sexually transmissible etiologic agent was hypothesized long before identification of human ...
openaire   +2 more sources

Clinical Validation of Four Point‐of‐Care High‐Risk HPV Assays, Including Two Reduced‐Valency Assays, for Cervical Cancer Screening in Low‐Resource Settings

International Journal of Cancer, Volume 159, Issue 8, Page 2004-2014, 15 October 2026.
High‐risk human papillomavirus (hrHPV) testing improves cervical cancer screening by facilitating earlier detection and prevention. In low‐resource settings, however, cost and increased referrals limit its use. At the same time, many new and more affordable assays lack validation.
Neerja Bhatla, MaryLuz Rol, Seema Singhal, Showket Hussain, Anushree Patil, Pranay Tanwar, Shalini Singh, Vikrant M. Bhor, Kiran Munne, Richa Vashishtha, Shachi Vashist, Eric Lucas, Richard Muwonge, Arianis Tatiana Ramírez, Anju Singh, Vikas Khan, Jyoti Rani, Nasera Firdausi, Sandeep Sisodiya, Rutuja Wakchaure, María Alejandra Picconi, Alejandro Calderón, Margo Bell, Annemie De Smet, Alex Vorsters, Gary M. Clifford, Madhavi Chandra, Jitendra Kumar, Partha Basu   +28 more
wiley   +1 more source